View ValuationWPD Pharmaceuticals 将来の成長Future 基準チェック /06現在、 WPD Pharmaceuticalsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長-11.6%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Jul 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$259k free cash flow). Shares are highly illiquid. Negative equity (-CA$714k). Revenue is less than US$1m. Market cap is less than US$10m (CA$579.9k market cap, or US$419.3k). Minor Risk Shareholders have been diluted in the past year (2.2% increase in shares outstanding).お知らせ • May 31WPD Pharmaceuticals Inc., Annual General Meeting, Aug 07, 2024WPD Pharmaceuticals Inc., Annual General Meeting, Aug 07, 2024. Location: british columbia, vancouver CanadaBoard Change • May 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Peter Novak was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jun 16WPD Pharmaceuticals Inc. announced that it has received CAD 0.3 million in fundingOn June 15, 2023, WPD Pharmaceuticals Inc. closed the transaction. Each Debenture is convertible into units at a conversion price of CAD 0.05 per Unit. Each Unit will consist of one common share and one share purchase warrant exercisable to purchase one additional common share at a price of CAD 0.05 for three years from the date of issuance of the Unit. The Debentures bear interest at the rate of 18% per annum compounded monthly until maturity and after default. The Debentures will mature on June 2, 2026. There were no finder’s fees paid in connection with the Private Placement. All securities issued in the Private Placement will be subject to a four-month hold period commencing on the closing date of the Private Placement.お知らせ • Jan 20WPD Pharmaceuticals Inc. Announces First Adult Patient Dosed in Phase 1B/2 Clinical Trial of Berubicin in the Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line TherapyWPD Pharmaceuticals Inc. announced that the first patient enrolled in the Phase 1B/2 clinical trial of intravenously infused Berubicin in the treatment of adult patients with recurrent glioblastoma multiforme after failure of standard first line therapy, has received the first dosing of Berubicin. This is a very important step in Berubicin clinical development. WPD Pharmaceuticals has initiated multicenter, open-label, Phase 1B/2 efficacy and safetystudy of Berubicin utilizing a Simon's 2-stage design to confirm the efficacy of a single arm of Berubicin treatment, administered at the recommended Phase 2 dose identified in Phase 1 studies, on the endpoint of ORR in up toapproximately 61 patients. Four polish clinical sites have been contracted for purpose of this clinical trials. A central reader will determine the radiologic responses for each patient according to m-RANO criteria. The responder criteria for this Simon's design will be based on objective response criteria defined as individual patients achieving CR or PR per m-RANO criteria within 6 months from baseline. Berubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin, was developed by Dr. Waldemar Priebe. Phase 1 clinical trial previously conducted by Reata Pharmaceuticals Inc. demonstrated positive responses after Berubicin treatment of brain cancer patients with one durable complete response.Is New 90 Day High Low • Jan 05New 90-day high: CA$0.31The company is up 27% from its price of CA$0.24 on 06 October 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period.Is New 90 Day High Low • Oct 02New 90-day low: CA$0.24The company is down 41% from its price of CA$0.41 on 03 July 2020. The Canadian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、WPD Pharmaceuticals は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測CNSX:WBIO - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/2024N/A000N/A6/30/2024N/A000N/A3/31/2024N/A000N/A12/31/2023N/A000N/A9/30/2023N/A6-1-1N/A6/30/2023N/A5-2-2N/A3/31/2023N/A4-2-2N/A12/31/2022N/A4-3-3N/A9/30/2022N/A-5-4-4N/A6/30/2022N/A-5-3-3N/A3/31/2022N/A-5-3-3N/A12/31/2021N/A-6-2-1N/A9/30/2021N/A-5-1-1N/A6/30/2021N/A-5-10N/A3/31/2021N/A-600N/A12/31/2020N/A-8-2-1N/A9/30/2020N/A-16-1-1N/A6/30/2020N/A-16-2-2N/A3/31/2020N/A-14-3-2N/A12/31/2019N/A-1200N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: WBIOの予測収益成長が 貯蓄率 ( 2.6% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: WBIOの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: WBIOの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: WBIOの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: WBIOの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: WBIOの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/08/05 21:42終値2025/05/08 00:00収益2024/09/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋WPD Pharmaceuticals Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jul 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$259k free cash flow). Shares are highly illiquid. Negative equity (-CA$714k). Revenue is less than US$1m. Market cap is less than US$10m (CA$579.9k market cap, or US$419.3k). Minor Risk Shareholders have been diluted in the past year (2.2% increase in shares outstanding).
お知らせ • May 31WPD Pharmaceuticals Inc., Annual General Meeting, Aug 07, 2024WPD Pharmaceuticals Inc., Annual General Meeting, Aug 07, 2024. Location: british columbia, vancouver Canada
Board Change • May 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Peter Novak was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 16WPD Pharmaceuticals Inc. announced that it has received CAD 0.3 million in fundingOn June 15, 2023, WPD Pharmaceuticals Inc. closed the transaction. Each Debenture is convertible into units at a conversion price of CAD 0.05 per Unit. Each Unit will consist of one common share and one share purchase warrant exercisable to purchase one additional common share at a price of CAD 0.05 for three years from the date of issuance of the Unit. The Debentures bear interest at the rate of 18% per annum compounded monthly until maturity and after default. The Debentures will mature on June 2, 2026. There were no finder’s fees paid in connection with the Private Placement. All securities issued in the Private Placement will be subject to a four-month hold period commencing on the closing date of the Private Placement.
お知らせ • Jan 20WPD Pharmaceuticals Inc. Announces First Adult Patient Dosed in Phase 1B/2 Clinical Trial of Berubicin in the Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line TherapyWPD Pharmaceuticals Inc. announced that the first patient enrolled in the Phase 1B/2 clinical trial of intravenously infused Berubicin in the treatment of adult patients with recurrent glioblastoma multiforme after failure of standard first line therapy, has received the first dosing of Berubicin. This is a very important step in Berubicin clinical development. WPD Pharmaceuticals has initiated multicenter, open-label, Phase 1B/2 efficacy and safetystudy of Berubicin utilizing a Simon's 2-stage design to confirm the efficacy of a single arm of Berubicin treatment, administered at the recommended Phase 2 dose identified in Phase 1 studies, on the endpoint of ORR in up toapproximately 61 patients. Four polish clinical sites have been contracted for purpose of this clinical trials. A central reader will determine the radiologic responses for each patient according to m-RANO criteria. The responder criteria for this Simon's design will be based on objective response criteria defined as individual patients achieving CR or PR per m-RANO criteria within 6 months from baseline. Berubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin, was developed by Dr. Waldemar Priebe. Phase 1 clinical trial previously conducted by Reata Pharmaceuticals Inc. demonstrated positive responses after Berubicin treatment of brain cancer patients with one durable complete response.
Is New 90 Day High Low • Jan 05New 90-day high: CA$0.31The company is up 27% from its price of CA$0.24 on 06 October 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Oct 02New 90-day low: CA$0.24The company is down 41% from its price of CA$0.41 on 03 July 2020. The Canadian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period.